Sporothrix brasiliensis and cats: understanding the disease and the promising potential of veterinary antifungal vaccination for a healthier future of both humans and animals

Abstract

Sporotrichosis is a subcutaneous fungal infection caused by species of the Sporothrix genus that affects both humans and animals. Sporothrix brasiliensis is a dimorphic fungus that exists in a mycelial and conidial phase in nature and is a yeast in its parasitic stage or when cultured at 37°C. Since its first identification in animals in 1907, the disease has become a significant concern, especially given the increasing number of cases in cats, particularly in urban areas. This has contributed to an increase in zoonotic transmission and the current epidemic of sporotrichosis in Brazil. Virulent strains of S. brasiliensis, combined with the increased susceptibility of felines, have exacerbated the public health challenge posed by sporotrichosis. As with other infectious diseases, immunomodulation presents a promising strategy for the prevention, treatment, and control of sporotrichosis in animals, potentially reducing zoonotic transmission. This review examines the role of cats in the transmission of this disease, the interactions between Sporothrix species and the host immune system, and the progress in the development of antifungal vaccines. We also highlight ongoing research into vaccine strategies. Ultimately, our goal is to encourage further dialog on effective approaches to control the rapid spread of zoonotic sporotrichosis.

Graphical Abstract

Sporothrix brasiliensis drives a growing sporotrichosis epidemic in Brazil, with domestic cats serving as the key zoonotic reservoir. This review examines the feline-driven transmission cycle, host‒pathogen immune interactions, and current progress in vaccine development. Immunomodulation through feline vaccination has emerged as a crucial strategy for breaking the transmission chain and controlling this public health threat.

Keywords

Cats / Humans / Sporothrix brasiliensis / Sporotrichosis / Vaccine / Zoonoses

References

[1] Almeida SR. Therapeutic monoclonal antibody for sporotrichosis. Frontiers in Microbiology, 2012, 3: 409

[2] Almeida JR, Kaihami GH, Jannuzzi GP, de Almeida SR. Therapeutic vaccine using a monoclonal antibody against a 70-kDa glycoprotein in mice infected with highly virulent Sporothrix schenckii and Sporothrix brasiliensis. Medical Mycology, 2015, 53(1): 42-50.

[3] Almeida JRF, Jannuzzi GP, Kaihami GH, Breda LCD, Ferreira KS, de Almeida SR. An immunoproteomic approach revealing peptides from Sporothrix brasiliensis that induce a cellular immune response in subcutaneous sporotrichosis. Science and Reports, 2018, 8(1): 3426

[4] Almeida-Paes R, Pimenta MA, Monteiro PC, Nosanchuk JD, Zancopé-Oliveira RM. Immunoglobulins G, M, and A against Sporothrix schenckii exoantigens in patients with sporotrichosis before and during treatment with itraconazole. Clinical and Vaccine Immunology, 2007, 14(9): 1149-1157.

[5] Almeida-Paes R, Oliveira MM, Freitas DF, Valle AC, Zancopé-Oliveira RM, Gutierrez-Galhardo MC. Sporotrichosis in Rio de Janeiro, Brazil: Sporothrix brasiliensis is associated with atypical clinical presentations. PLoS Neglected Tropical Diseases, 2014, 8(9e3094

[6] Alvarez CM, Oliveira MME, Pires RH. Sporotrichosis: A review of a neglected disease in the last 50 years in Brazil. Microorganisms, 2022, 10(11): 2152

[7] Barros MBL, Schubach TP, Coll JO, Gremião ID, Wanke B, Schubach A. Sporotrichosis: Development and challenges of an epidemic. Revista Panamericana De Salud Publica, 2010, 276): 455-460.

[8] Bastos, F.A.G.D., Cognialli, R.C., Farias, M.R., Monti, F.S., Wu, K., Queiroz-Telles, F., 2022. Spread of Sporothrix spp. through respiratory droplets from infected cats: a potential route of transmission. Med. Mycol. 60(7):myac079. https://doi.org/10.1093/mmy/myac079.

[9] Batista-Duharte A, Téllez-Martínez D, Andrade RC, Portuondo DL, Jellmayer JA, Polesi MC, Carlos IZ. Sporothrix brasiliensis induces a more severe disease associated with sustained Th17 and regulatory T cells responses than Sporothrix schenckii sensu stricto in mice. Fungal Biology, 2018, 122(12): 1163-1170.

[10] Batista-Duharte A, Sendra L, Herrero MJ, Portuondo DL, Téllez-Martínez D, Olivera G, Fernández-Delgado M, Javega B, Herrera G, Martínez A, et al. . Foxp3 silencing with antisense oligonucleotide improves immunogenicity of an adjuvanted recombinant vaccine against Sporothrix schenckii. International Journal of Molecular Sciences, 2021, 22(7): 3470

[11] Batista-Duharte A, Téllez-Martínez D, Portuondo DL, Carlos IZ. Selective depletion of regulatory T cells enhances the immunogenicity of a recombinant-based vaccine against Sporothrix spp. Frontiers in Cellular and Infection Microbiology, 2022, 12: 1084526

[12] Bongomin F, Gago S, Oladele RO, Denning DW. Global and multinational prevalence of fungal diseases—Estimate precision. Journal of Fungi, 2017, 3(457

[13] Brown AJ, Leach MD, Nicholls S. The relevance of heat shock regulation in fungal pathogens of humans. Virulence, 2010, 14): 330-332.

[14] Boehringer Ingelheim Vetmedica GmbH. Insol® Dermatophyton. 2020. Available from: https://www.vetmedica.de/produkte-tierarzt/Pferd/insol-dermatophyton/3667.

[15] Carlos IZ, Sgarbi DB, Santos GC, Placeres MC. Sporothrix schenckii lipid inhibits macrophage phagocytosis: Involvement of nitric oxide and tumor necrosis factor-alpha. Scandinavian Journal of Immunology, 2003, 57(3): 214-220.

[16] Chaves AR, Campos MP, Barros MB, do Carmo CN, Gremião ID, Pereira SA, Schubach TM. Treatment abandonment in feline sporotrichosis – Study of 147 cases. Zoonoses and Public Health, 2013, 60(2): 149-153.

[17] Chechi J, Costa FAC, Figueiredo JM, Souza CM, Valdez AF, Zamith-Miranda D, Camara AC, Taborda CP, Nosanchuk JD. Vaccine development for pathogenic fungi: Current status and future directions. Expert Review of Vaccines, 2023, 22(1): 1136-1153.

[18] De Beer ZW, Duong TA, Wingfield MJ. The divorce of Sporothrix and Ophiostoma: Solution to a problematic relationship. Studies in Mycology, 2016, 83: 165-191.

[19] De Bernardis F, Amacker M, Arancia S, Sandini S, Gremion C, Zurbriggen R, Moser C, Cassone A. A virosomal vaccine against candidal vaginitis: Immunogenicity, efficacy and safety profile in animal models. Vaccine, 2012, 30(30): 4490-4498.

[20] De Bernardis F, Graziani S, Tirelli F, Antonopoulou S. Candida vaginitis: Virulence, host response and vaccine prospects. Medical Mycology, 2018, 56(Suppl 1myx139

[21] DeBoer DJ, Moriello KA, Blum JL, Volk LM, Bredahl LK. Safety and immunologic effects after inoculation of inactivated and combined live-inactivated dermatophytosis vaccines in cats. American Journal of Veterinary Research, 2002, 63(11): 1532-1537.

[22] Edwards JE, Schwartz MM, Schmidt CS, Sobel JD, Nyirjesy P, Schodel F, Marchus E, Lizakowski M, DeMontigny EA, Hoeg J, et al. . A fungal immunotherapeutic vaccine (NDV-3A) for treatment of recurrent vulvovaginal candidiasis—a phase 2 randomized, double-blind, placebo-controlled trial. Clinical Infectious Diseases, 2018, 66(12): 1928-1936.

[23] Fernandes GF, Santos PO, Amaral CC, Sasaki AA, Godoy-Martinez P, Camargo ZP. Characteristics of 151 Brazilian Sporothrix schenckii isolates from 5 different geographic regions of Brazil: A forgotten and re-emergent pathogen. The Open Mycology Journal, 2009, 3: 48-58.

[24] Fernandes GF, dos Santos PO, Rodrigues AM, Sasaki AA, Burger E, de Camargo ZP. Characterization of virulence profile, protein secretion and immunogenicity of different Sporothrix schenckii sensu stricto isolates compared with S. globosa and S. brasiliensis species. Virulence, 2013, 4(3): 241-249.

[25] Fernandes B, Caligiorne RB, Coutinho DM, Gomes RR, Rocha-Silva F, Machado AS, Santrer EFR, Assunção CB, Guimarães CF, Laborne MS, et al. . A case of disseminated sporotrichosis caused by Sporothrix brasiliensis. Medical Mycology Case Reports, 2018, 21: 34-36.

[26] Flammineis, D.C., Cachutt, A., Alvarado, P., Cavallera, E., 2022. Actualización de la epidemiología de esporotricosis em Venezuela. Dermatol. Venez. 60(1). https://revista.svderma.org/index.php/ojs/article/view/1500/1488

[27] Franco DL, Nascimento RC, Ferreira KS, Almeida SR. Antibodies against Sporothrix schenckii enhance TNF-α production and killing by macrophages. Scandinavian Journal of Immunology, 2012, 75(2): 142-146.

[28] Gremião IDF, Menezes RC, Schubach TM, Figueiredo AB, Cavalcanti MC, Pereira SA. Feline sporotrichosis: Epidemiological and clinical aspects. Medical Mycology, 2015, 53(1): 15-21.

[29] Gremião IDF, Miranda LH, Reis EG, Rodrigues AM, Pereira SA. Zoonotic epidemic of sporotrichosis: Cat to human transmission. PLoS Pathogens, 2017, 13(1e1006077

[30] Gremião IDF, Rocha EMS, Montenegro H, Carneiro AJB, Xavier MO, de Farias MR, Monti F, Mansho W, Pereira RH, Pereira SA, et al. . Guideline for the management of feline sporotrichosis caused by Sporothrix brasiliensis and literature revision. Brazilian Journal of Microbiology, 2021, 521): 107-124.

[31] Guzman-Beltran S, Perez-Torres A, Coronel-Cruz C, Torres-Guerrero H. Phagocytic receptors on macrophages distinguish between different Sporothrix schenckii morphotypes. Microbes and Infection, 2012, 14(12): 1093-1101.

[32] Hektoen L, Perkins CF. Refractory subcutaneous abscesses caused by Sporothrix schenckii: A new pathogenic fungus. The Journal of Experimental Medicine, 1900, 5(1): 77-89.

[33] Inácio MM, Moreira ALE, Cruz-Leite VRM, Mattos K, Silva LOS, Venturini J, Ruiz OH, Ribeiro-Dias F, Weber SS, Soares CMA, et al. . Fungal vaccine development: State of the art and perspectives using immunoinformatics. J. Fungi., 2023, 9(6): 633

[34] Jellmayer JA, Ferreira LS, Manente FA, Gonçalves AC, Polesi MC, Batista-Duharte A, Carlos IZ. Dectin-1 expression by macrophages and related antifungal mechanisms in a murine model of Sporothrix schenckii sensu stricto systemic infection. Microbial Pathogenesis, 2017, 110: 78-84.

[35] Jones KE, Patel NG, Levy MA, Storygard A, Balk D, Gittleman JL, Daszak P. Global trends in emerging infectious diseases. Nature, 2008, 451(7181): 990-993.

[36] Kajiwara H, Saito M, Ohga S, Uenotsuchi T, Yoshida S. Impaired host defense against Sporothrix schenckii in mice with chronic granulomatous disease. Infection and Immunity, 2004, 72(9): 5073-5079.

[37] Kohler JR, Casadevall A, Perfect J. The spectrum of fungi that infects humans. Cold Spring Harbor Perspectives in Medicine, 2015, 5(7a019273

[38] Komi DEA, Sharma L, Dela Cruz CS. Chitin and its effects on inflammatory and immune responses. Clinical Reviews in Allergy and Immunology, 2018, 542): 213-223.

[39] Lecca LO, Paiva MT, Oliveira CSF, Morais MHF, Azevedo MI, Bastos CVE, Keller KM, Ecco R, Alves MRS, Pais GCT, et al. . Associated factors and spatial patterns of the epidemic sporotrichosis in a high density human populated area: A cross-sectional study from 2016 to 2018. Preventive Veterinary Medicine, 2020, 181104939

[40] Levy DA, Bohbot JM, Catalan F, Normier G, Pinel AM, Dussourd d'Hinterland L. Phase II study of D.651, an oral vaccine designed to prevent recurrences of vulvovaginal candidiasis. Vaccine, 1989, 7(4): 337-340.

[41] LimmaTech Biologics AG, 2023. Assessing the safety, immune response, and early efficacy of a Candida vaccine in women with recurrent vulvovaginal candidiasis: a randomized controlled study. NCT06190509. clinicaltrials.gov.

[42] Liu, K., Zhao, L., Peng, D., Fu, Z. F., Meng, F.L. 2025. How can ‘exotic pets’ be dealt with in the context of one world, one health?. Animal Diseases 5:13. https://doi.org/10.1186/s44149-025-00167.

[43] Lopes-Bezerra LM, Walker LA, Niño-Veja G, Mora-Montes HM, Neves GWP, Villalobos-Duno H, Barreto L, Garcia K, Franco B, Martínez-Álvarez JA, et al. . Cell walls of the dimorphic fungal pathogens Sporothrix schenckii and Sporothrix brasiliensis exhibit bilaminate structures and sloughing of extensive and intact layers. PLoS Neglected Tropical Diseases, 2018, 12(5e0006169

[44] Lund A, DeBoer DJ. Immunoprophylaxis of dermatophytosis in animals. Mycopathologia, 2008, 1665–6): 407-424.

[45] Lund A, Bratberg AM, Næss B, Gudding R. Control of bovine ringworm by vaccination in Norway. Veterinary Immunology and Immunopathology, 2014, 158(1–2): 37-45.

[46] Lutz A, Splendore A. On a mycosis observed in men and mice: Contribution to the knowledge of the so-called sporotrichosis. Revista De Medicina De Sao Paulo, 1907, 21: 443-450

[47] Macêdo-Sales PA, Souto SRLS, Destefani CA, Lucena RP, Machado RLD, Pinto MR, Rodrigues AM, Lopes-Bezerra LM, Rocha EMS, Baptista ARS. Domestic feline contribution in the transmission of Sporothrix in Rio de Janeiro State, Brazil: A comparison between infected and noninfected populations. BMC Veterinary Research, 2018, 14(1): 19.

[48] Martínez-Álvarez JA, Pérez-García LA, Mellado-Mojica E, López MG, Martínez-Duncker I, Lópes-Bezerra LM, Mora-Montes HM. Sporothrix schenckii sensu stricto and Sporothrix brasiliensis are differentially recognized by human peripheral blood mononuclear cells. Frontiers in Microbiology, 2017, 8: 843.

[49] Martínez-Duncker I, Chiodo F, Mora-Montes HM, Vasta GR. Editorial: The role of glycans in infectious disease. Frontiers in Microbiology, 2022, 13921436

[50] Mendoza L, Mandy W, Glass R. An improved Pythium insidiosum-vaccine formulation with enhanced immunotherapeutic properties in horses and dogs with pythiosis. Vaccine, 2003, 2121–22): 2797-2804.

[51] Mesquita VA, Talhari S, Leturiondo AL, de Souza GC, de Brito EM, de Andrade SL, Fernandes DCL, Frota MZM, Cruz RCDS, Guimarães JAR, et al. . Zoonotic sporotrichosis outbreak: Emerging public health threat in the Amazon State. Brazil. Plos Negl. Trop. Dis., 2024, 18(6e0012328

[52] Miranda LHM, Santiago MA, Schubach TMP, Morgado FN, Pereira SA, Oliveira RVC, Conceição-Silva F. Severe feline sporotrichosis associated with an increased population of CD8low cells and a decrease in CD4⁺ cells. Medical Mycology, 2016, 54(1): 29-39.

[53] Montenegro H, Rodrigues AM, Dias MA, Silva EA, Bernardi F, Camargo ZP. Feline sporotrichosis due to Sporothrix brasiliensis: An emerging animal infection in São Paulo. Brazil. BMC Vet. Res., 2014, 10: 269.

[54] Nascimento RC, Almeida SR. Humoral immune response against soluble and fractionate antigens in experimental sporotrichosis. FEMS Immunology and Medical Microbiology, 2005, 43(2): 241-247.

[55] Nascimento, R.C., Espíndola, N.M., Castro, R.A., Teixeira, P.A., Loureiro y Penha, C.V., Lopes-Bezerra, L.M., Almeida, S.R., 2008. Passive immunization with monoclonal antibody against a 70-kDa putative adhesin of Sporothrix schenckii induces protection in murine sporotrichosis. Eur. J. Immunol. 38(11):3080–9. https://doi.org/10.1002/eji.200838513.

[56] Negrini TC, Ferreira LS, Arthur RA, Alegranci P, Placeres MC, Spolidorio LC, Carlos IZ. Influence of TLR-2 in the immune response in the infection induced by fungus Sporothrix schenckii. Immunologic Investigations, 2014, 43(4): 370-390.

[57] Oliveira LVN, Wang R, Specht CA, Levitz SM. Vaccines for human fungal diseases: Close but still a long way to go. NPJ Vaccines, 2021, 6(1): 33

[58] O'Meara TR, Veri AO, Ketela T, Jiang B, Roemer T, Cowen LE. Global analysis of fungal morphology exposes mechanisms of host cell escape. Nature Communications, 2015, 6: 6741

[59] Orofino-Costa R, Macedo PM, Rodrigues AM, Bernardes-Engemann AR. Sporotrichosis: An update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics. Anais Brasileiros De Dermatologia, 2017, 923): 606-620.

[60] Pappagianis D. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. American Review of Respiratory Disease, 1993, 148(3): 656-660.

[61] Portuondo DL, Batista-Duharte A, Ferreira LS, Martínez DT, Polesi MC, Duarte RA, de Paula E, Silva AC, Marcos CM, Almeida AM, et al. . A cell wall protein-based vaccine candidate induce protective immune response against Sporothrix schenckii infection. Immunobiology, 2016, 221(2): 300-309.

[62] Portuondo, D.L., Batista-Duharte, A., Ferreira, L.S., de Andrade, C.R., Quinello, C., Téllez-Martínez, D., de Aguiar Loesch, M.L., Carlos, I.Z., 2017. Comparative efficacy and toxicity of two vaccine candidates against Sporothrix schenckii using either Montanide™ Pet Gel A or aluminum hydroxide adjuvants in mice. Vaccine. 35(35 Pt B):4430–6. https://doi.org/10.1016/j.vaccine.2017.05.046.

[63] Portuondo, D.L., Dores-Silva, P.R., Ferreira, L.S., de Oliveira, C.S., Téllez-Martínez, D., Marcos, C.M., de Aguiar, M.L.L., Guzmán, F., Gava, L.M., Borges, J.C., et al., 2019. Immunization with recombinant enolase of Sporothrix spp. (rSsEno) confers effective protection against sporotrichosis in mice. Sci. Rep. 9(1):17101. https://doi.org/10.1038/s41598-019-53135-z.

[64] Queiroz-Telles F, Fahal AH, Falci DR, Caceres DH, Chiller T, Pasqualotto AC. Neglected endemic mycoses. The Lancet Infectious Diseases, 2017, 17(11): e367-e377.

[65] Quinello C, Ferreira LS, Picolli I, Loesch ML, Portuondo DL, Batista-Duharte A, Carlos IZ. Sporothrix schenckii cell wall proteins-stimulated BMDCs are able to induce a Th1-prone cytokine profile in vitro. Journal of Fungi, 2018, 4(3106

[66] Rodrigues C, Plotkin S. Impact of vaccines; Health, economic and social perspectives. Frontiers in Microbiology, 2020, 11: 1526.

[67] Rodrigues ML, Nimrichter L, Oliveira DL, Nosanchuk JD, Casadevall A. Vesicular trans-cell wall transport in fungi: A mechanism for the delivery of virulence-associated macromolecules?. Lipid Insights., 2008, 2: 27-40.

[68] Rodrigues AM, Teixeira MM, Hoog GS, Schubach TM, Pereira SA, Fernandes GF, Bezerra LM, Felipe MS, de Camargo ZP. Phylogenetic analysis reveals a high prevalence of Sporothrix brasiliensis in feline sporotrichosis outbreaks. PLoS Neglected Tropical Diseases, 2013, 7(6e2281

[69] Rodrigues AM, Della-Terra PP, Gremião ID, Pereira SA, Orofino-Costa R, de Camargo ZP. The threat of emerging and re-emerging pathogenic Sporothrix species. Mycopathologia, 2020, 1855): 813-842.

[70] Rodrigues AM, Gonçalves SS, de Carvalho JA, Borba-Santos LP, Rozental S, Camargo ZP. Current progress on epidemiology, diagnosis, and treatment of sporotrichosis and their future trends. J. Fungi., 2022, 8(8): 776

[71] Rodrigues AM, Hagen F, Camargo ZP. A spotlight on Sporothrix and sporotrichosis. Mycopathologia, 2022, 1875–6): 407-411.

[72] Romani L. Immunity to fungal infections. Nature Reviews Immunology, 2004, 4(1): 1-23.

[73] Rossato L, Moreno LF, Jamalian A, Stielow B, de Almeida SR, de Hoog S, Freeke J. Proteins potentially involved in immune evasion strategies in Sporothrix brasiliensis elucidated by ultrahigh-resolution mass spectrometry. M Sphere, 2018, 3(3e00514–17

[74] Rossato L, Santos SSD, Ferreira LG, de Almeida SR. The importance of toll-like receptor 4 during experimental Sporothrix brasiliensis infection. Medical Mycology, 2019, 57(4): 489-495.

[75] Rossato L, Santos SS, Ferreira LG, Almeida RS. The impact of the absence of toll-like receptor-2 during Sporothrix brasiliensis infection. Journal of Medical Microbiology, 2019, 68(1): 87-94.

[76] Sanchotene KO, Madrid IM, Klafke GB, Bergamashi M, Della-Terra PP, Rodrigues AM, de Camargo ZP, Xavier MO. Sporothrix brasiliensis outbreaks and the rapid emergence of feline sporotrichosis. Mycoses, 2015, 58(11): 652-658.

[77] Santos MT, Nascimento LFJ, Barbosa AAT, Martins MP, Tunon GIL, Santos POM, Dantas-Torres F, Dolabella SS. The rising incidence of feline and cat-transmitted sporotrichosis in Latin America. Zoonoses and Public Health, 2024, 71(6): 609-619.

[78] Schenck RB. On refractory subcutaneous abscesses caused by a fungus possibly related to sporotrichia. Bulletin of the Johns Hopkins Hospital, 1898, 9: 286-290

[79] Schmidt CS, White CJ, Ibrahim AS, Filler SG, Fu Y, Yeaman MR, Edwards JE, Hennessey JP. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine., 2012, 30(50): 7594-7600.

[80] Schubach TM, Schubach AO, Cuzzi-Maya T, Okamoto T, Reis RS, Monteiro PC, Gutierrez-Galhardo MC, Wanke B. Pathology of sporotrichosis in 10 cats in Rio de Janeiro. The Veterinary Record, 2003, 152(6): 172-175.

[81] Scott EN, Muchmore HG. Immunoblot analysis of antibody responses to Sporothrix schenckii. Journal of Clinical Microbiology, 1989, 27(2): 300-304.

[82] Seyedmousavi S, Bosco SMG, de Hoog S, Ebel F, Elad D, Gomes RR, Jacobsen ID, Jensen HE, Martel A, Mignon B, et al. . Fungal infections in animals: A patchwork of different situations. Medical Mycology, 2018, 56(Suppl 1): 165-187.

[83] Shang, Q.H., Gao, W.H., Zhang, X.T., Zhao, J.Q., Wu, Y., Li, H.Q., Zhou, M., Fu, Z.F., Zhang, C.G., Zhao, L. 2024. Investigation of the epidemiology, pathogenicity and immunogenicity of Bordetella bronchiseptica isolated from cats and dogs in China from 2021 to 2023. Animal Diseases 4:16. https://doi.org/10.1186/s44149-024-00120-3.

[84] Shubitz LF, Robb EJ, Powell DA, Bowen RA, Bosco-Lauth A, Hartwig A, Porter SM, Trinh H, Moale H, Bielefeldt-Ohmann H, et al. . Δcps1 vaccine protects dogs against experimentally induced coccidioidomycosis. Vaccine, 2021, 39(48): 6894-6901.

[85] Silva MB, Costa MM, Torres CC, Galhardo MC, Valle AC, Magalhães MA, Sabroza PC, Oliveira RM. Urban sporotrichosis: A neglected epidemic in Rio de Janeiro, Brazil [Urban sporotrichosis: A neglected epidemic in Rio de Janeiro, Brazil]. Cadernos De Saúde Pública, 2012, 28(10): 1867-1880.

[86] Snarr BD, Qureshi ST, Sheppard DC. Immune recognition of fungal polysaccharides. Journal of Fungi, 2017, 3(347

[87] Sterkel AK, Lorenzini JL, Fites JS, Vignesh KS, Sullivan TD, Wuthrich M, Brandhorst T, Hernandez-Santos N, Deepe GS, Klein BS. Fungal mimicry of a mammalian aminopeptidase disables innate immunity and promotes pathogenicity. Cell Host & Microbe, 2016, 193): 361-374.

[88] Taylor LH, Latham SM, Woolhouse ME. Risk factors for human disease emergence. Philosophical Transactions of the Royal Society of London. Series b, Biological Sciences, 2001, 356(1411): 983-989.

[89] Teixeira MM, de Almeida LG, Kubitschek-Barreira P, Alves FL, Kioshima ES, Abadio AK, Fernandes L, Derengowski LS, Ferreira KS, Souza RC, et al. . Comparative genomics of the major fungal agents of human and animal sporotrichosis: Sporothrix schenckii and Sporothrix brasiliensis. BMC Genomics, 2014, 15: 943.

[90] Téllez-Martínez D, Portuondo DL, Loesch ML, Batista-Duharte A, Zeppone IC. A recombinant enolase-Montanide™ PetGel A vaccine promotes a protective Th1 immune response against a highly virulent Sporothrix schenckii by toluene exposure. Pharmaceutics., 2019, 11(3): 144

[91] Thitithanyanont A, Mendoza L, Chuansumrit A, Pracharktam R, Laothamatas J, Sathapatayavongs B, Lolekha S, Ajello L. Use of an immunotherapeutic vaccine to treat a life-threatening human arteritic infection caused by Pythium insidiosum. Clinical Infectious Diseases, 1998, 276): 1394-1400.

[92] Tian Y, Hu D, Li Y, Yang L. Development of therapeutic vaccines for the treatment of diseases. Mol. Biomed., 2022, 3(1): 8.

[93] Tizard, I.R., 2020. Feline vaccines. In: Tizard IR, editor. Vaccines for veterinarians. Elsevier; p. 167–78.

[94] Ueno K, Yanagihara N, Shimizu K, Miyazaki Y. Vaccines and protective immune memory against cryptococcosis. Biological & Pharmaceutical Bulletin, 2020, 43(2): 230-239.

[95] Underhill DM, Gantner B. Integration of toll-like receptor and phagocytic signaling for tailored immunity. Microbes and Infection, 2004, 6(15): 1368-1373.

[96] Ural K, Ulutas B. Immunization with Trichophyton verrucosum vaccine in hunter/jumper and dressage horses with naturally occurring Trichophyton equinum infection: A prospective, randomized, double-blinded, placebo-controlled clinical trial. Journal of Equine Veterinary Science, 2008, 28(10): 590-593.

[97] Vitale KR, Behnke AC, Udell MAR. Attachment bonds between domestic cats and humans. Current Biology, 2019, 29(18): R864-R865.

[98] Wanachiwanawin W, Mendoza L, Visuthisakchai S, Mutsikapan P, Sathapatayavongs B, Chaiprasert A, Suwanagool P, Manuskiatti W, Ruangsetakit C, Ajello L. Efficacy of immunotherapy using antigens of Pythium insidiosum in the treatment of vascular pythiosis in humans. Vaccine, 2004, 22(27–28): 3613-3621.

[99] World Health Organization. 2022a. WHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; License: CC BY-NC-SA 3.0 IGO. https://iris.who.int/bitstream/handle/10665/363682/9789240060241-eng.pdf?sequence=1.

[100] World Health Organization. 2022b. Ending the neglect to attain the Sustainable Development Goals: a strategic framework for integrated control and management to skin-related neglected tropical diseases. Geneva: World Health Organization; License: CC BY-NC-SA 3.0 IGO. https://www.who.int/publications/i/item/9789240051423.

[101] Wüthrich M, Krajaejun T, Shearn-Bochsler V, Bass C, Filutowicz HI, Legendre AM, Klein BS. Safety, tolerability, and immunogenicity of a recombinant, genetically engineered, live-attenuated vaccine against canine blastomycosis. Clinical and Vaccine Immunology, 2011, 18(5): 783-789.

[102] Zhou X, Rodrigues AM, Feng P, Hoog GS. Global ITS diversity in the Sporothrix schenckii complex. Fungal Divers., 2014, 66: 153-165.

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Fundação de Amparo à Pesquisa do Estado de Minas Gerais

National Council for Scientific and Technological Development (CNPq)

RIGHTS & PERMISSIONS

The Author(s)